search
Back to results

A Home-based Rehabilitation in ARSACS (PACE-ARSCS)

Primary Purpose

Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay

Status
Recruiting
Phase
Not Applicable
Locations
Canada
Study Type
Interventional
Intervention
Rehabilitation
Sponsored by
Université de Sherbrooke
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional supportive care trial for Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay focused on measuring ARSACS

Eligibility Criteria

18 Years - 50 Years (Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: ARSACS diagnosis must be confirmed by genetic analysis; Women and men, aged between 18 and 50 years old; Be able to perform the sit-to-stand transfer; Consent of the neurologist must be given to participate in this study; Must reside in the Saguenay-Lac-St-Jean region; Subjects must be able to give their consent freely and voluntarily. Exclusion Criteria: Patients who already meet physical activity (PA) recommendations (150 min of moderate to high intensity PA/week) or already participate in a rehabilitation program are excluded; Remain in a care facility; Do not speak English or French; Have another diagnosis causing physical limitations; Are pregnant.

Sites / Locations

  • Groupe de recherche interdisciplinaire sur les maladies neuromusculairesRecruiting

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Control followed by intervention phase

Arm Description

All participants will participate in 2 phases : control phase (12-week usual care) followed by an intervention phase (12-week home-based rehabilitation program). The rehabilitation program consists of three domains of exercises divided by levels of difficulty: sitting balance (16 levels), standing balance (21 levels) and sit-to-stand transfer (12 levels), including 67 exercises. Each individualized home-based rehabilitation program will include 3 to 6 exercises, for a total duration of 15 to 20 minutes.

Outcomes

Primary Outcome Measures

Change in sitting balance
Measured with the Ottawa sitting scale, score range 0-40, a higher score indicates a better outcome
Change in balance
Measured with the Berg Balance Scale, score range 0-56, a higher score indicates better balance
Change in walking speed
Change in the walking speed, measured with the time to walk 10 meters at self-selected and maximum speed

Secondary Outcome Measures

Change in the balance confidence
Measured with the modified Activities-specific Balance Confidence (ABC) Scale, score range 0-100, 0 indicates no confidence and 100 is full confidence
Change in the number of falls
Number of self-reported falls in the last month
Change in the lower limb coordination
Number of touched targets in a 30 second period with each foot, measured with the Lower Extremity MOtor COordination Test (LEMOCOT)
Change in the number of sit-to-stand performed in 30 seconds
Number of complete sit-to-stand performed in 30 seconds without the help of arms
Change in the time required to ascent 10 stairs
Time required to ascent 10 stairs, measured with the 10 Stairs Ascent
Change in the time required to descent 10 stairs
Time required to descent 10 stairs, measured with the 10 Stairs Descent
Change in the life space
Measured with the Life Space Assessment (LSA), score range 0-120, a higher score indicates higher level of mobility in the next five areas: outside the bedroom, outside the house, in the neighborhood, outside of the neighborhood but in town, and outside town during the past four weeks
Change in the upper limb coordination
Number of finger touched targets in a 20 second period of each side, measured with the Standardized Finger-Nose Test (SFNT)
Change in social participation
The performance in activities of daily living, measured with the Assessment of Life Habits (LIFE-H), score range 0-9
Change in the Scale for the assessement and rating of ataxia (SARA)
Measured with the Scale for the assessment and rating of ataxia (SARA), score range 0-40, higher score indicates higher ataxia severity
Measure of the usability of the program and hardware
Measured with the French System Usability Scale (F-SUS), original score range 0-40 converted to 0-100, a SUS score above a 68 would be considered above average and anything below 68 is below average
Change in sleep components
The sleep components are measured with an actigraphy watch
Change in mobility components
The changes in mobility components are measured with an actigraphy watch
Change in the adductor hip muscle group spasticity
Change in the adductor hip muscle group spasticity, measured with the Modified Ashworth Scale
Change in the knee extensor muscle group spasticity
Change in the knee extensor muscle group spasticity, measured with the Modified Ashworth Scale
Change in the knee flexor muscle group spasticity
Change in the knee flexor muscle group spasticity, measured with the Modified Ashworth Scale
Change in the plantar flexor muscle group spasticity
Change in the plantar flexor muscle group spasticity, measured with the Modified Ashworth Scale
Sum of lower limb muscle spasticity
Sum of the spasticity results obtained for the adductor hip, knee extensor, knee flexor and plantar flexor muscle groups

Full Information

First Posted
March 3, 2023
Last Updated
May 23, 2023
Sponsor
Université de Sherbrooke
search

1. Study Identification

Unique Protocol Identification Number
NCT05768750
Brief Title
A Home-based Rehabilitation in ARSACS
Acronym
PACE-ARSCS
Official Title
A Home-based Rehabilitation Program to Counter the Motor Impairments and Activity Limitations Experienced by People With Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay
Study Type
Interventional

2. Study Status

Record Verification Date
May 2023
Overall Recruitment Status
Recruiting
Study Start Date
December 1, 2022 (Actual)
Primary Completion Date
December 1, 2024 (Anticipated)
Study Completion Date
December 1, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Université de Sherbrooke

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
48 participants (24 women and 24 men) with autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS) will participate in 2 phases : control phase (12-week usual care) and intervention phase (12-week home-based rehabilitation program). The participants will be evaluated at baseline, week 12 (end of control phase) and week 24 (end of intervention phase) to quantify the effects of an individualized home-based rehabilitation program. Participants will also participate on a focus group at the end of the program to evaluate the acceptability of the program and the perceived changes.
Detailed Description
Co-creation phase: Preceding the intervention, a co-creation phase involving healthcare professionals (3), patient-partners (2), and ARSACS researchers (3) will be conducted to develop the exercises for the rehabilitation program and the evaluation scale to determine the level of difficulty of each exercise assigned to participants. Intervention phase: Random sampling stratified by gender and level of indoor mobility (unassisted walking, assisted walking, wheelchair) from the Neuromuscular Clinic's registry of 48 participants (24 women and 24 men) will be conducted. Control phase: All participants will be asked to maintain their usual activities for 12 weeks. Intervention phase: All participants recruited to the project will complete the home-based rehabilitation program assigned to them for 12 weeks, unsupervised, 20 minutes 3 times a week. Follow-up calls by a physiotherapist will be conducted at weeks 2, 4, 6, 8, 10 and 12.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay
Keywords
ARSACS

7. Study Design

Primary Purpose
Supportive Care
Study Phase
Not Applicable
Interventional Study Model
Sequential Assignment
Model Description
Participants will participate in 2 phases : control phase (12-week usual care) followed by an intervention phase (12-week home-based rehabilitation program).
Masking
None (Open Label)
Allocation
N/A
Enrollment
48 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Control followed by intervention phase
Arm Type
Experimental
Arm Description
All participants will participate in 2 phases : control phase (12-week usual care) followed by an intervention phase (12-week home-based rehabilitation program). The rehabilitation program consists of three domains of exercises divided by levels of difficulty: sitting balance (16 levels), standing balance (21 levels) and sit-to-stand transfer (12 levels), including 67 exercises. Each individualized home-based rehabilitation program will include 3 to 6 exercises, for a total duration of 15 to 20 minutes.
Intervention Type
Other
Intervention Name(s)
Rehabilitation
Intervention Description
X
Primary Outcome Measure Information:
Title
Change in sitting balance
Description
Measured with the Ottawa sitting scale, score range 0-40, a higher score indicates a better outcome
Time Frame
Baseline, week 12, week 24
Title
Change in balance
Description
Measured with the Berg Balance Scale, score range 0-56, a higher score indicates better balance
Time Frame
Baseline, week 12, week 24
Title
Change in walking speed
Description
Change in the walking speed, measured with the time to walk 10 meters at self-selected and maximum speed
Time Frame
Baseline, week 12, week 24
Secondary Outcome Measure Information:
Title
Change in the balance confidence
Description
Measured with the modified Activities-specific Balance Confidence (ABC) Scale, score range 0-100, 0 indicates no confidence and 100 is full confidence
Time Frame
Baseline, week 12, week 24
Title
Change in the number of falls
Description
Number of self-reported falls in the last month
Time Frame
Baseline, week 12, week 24
Title
Change in the lower limb coordination
Description
Number of touched targets in a 30 second period with each foot, measured with the Lower Extremity MOtor COordination Test (LEMOCOT)
Time Frame
Baseline, week 12, week 24
Title
Change in the number of sit-to-stand performed in 30 seconds
Description
Number of complete sit-to-stand performed in 30 seconds without the help of arms
Time Frame
Baseline, week 12, week 24
Title
Change in the time required to ascent 10 stairs
Description
Time required to ascent 10 stairs, measured with the 10 Stairs Ascent
Time Frame
Baseline, week 12, week 24
Title
Change in the time required to descent 10 stairs
Description
Time required to descent 10 stairs, measured with the 10 Stairs Descent
Time Frame
Baseline, week 12, week 24
Title
Change in the life space
Description
Measured with the Life Space Assessment (LSA), score range 0-120, a higher score indicates higher level of mobility in the next five areas: outside the bedroom, outside the house, in the neighborhood, outside of the neighborhood but in town, and outside town during the past four weeks
Time Frame
Baseline, week 12, week 24
Title
Change in the upper limb coordination
Description
Number of finger touched targets in a 20 second period of each side, measured with the Standardized Finger-Nose Test (SFNT)
Time Frame
Baseline, week 12, week 24
Title
Change in social participation
Description
The performance in activities of daily living, measured with the Assessment of Life Habits (LIFE-H), score range 0-9
Time Frame
Baseline, week 12, week 24
Title
Change in the Scale for the assessement and rating of ataxia (SARA)
Description
Measured with the Scale for the assessment and rating of ataxia (SARA), score range 0-40, higher score indicates higher ataxia severity
Time Frame
Baseline, week 12, week 24
Title
Measure of the usability of the program and hardware
Description
Measured with the French System Usability Scale (F-SUS), original score range 0-40 converted to 0-100, a SUS score above a 68 would be considered above average and anything below 68 is below average
Time Frame
Week 24
Title
Change in sleep components
Description
The sleep components are measured with an actigraphy watch
Time Frame
Week 12, week 24
Title
Change in mobility components
Description
The changes in mobility components are measured with an actigraphy watch
Time Frame
Week 12, week 24
Title
Change in the adductor hip muscle group spasticity
Description
Change in the adductor hip muscle group spasticity, measured with the Modified Ashworth Scale
Time Frame
Baseline, week 12, week 24
Title
Change in the knee extensor muscle group spasticity
Description
Change in the knee extensor muscle group spasticity, measured with the Modified Ashworth Scale
Time Frame
Baseline, week 12, week 24
Title
Change in the knee flexor muscle group spasticity
Description
Change in the knee flexor muscle group spasticity, measured with the Modified Ashworth Scale
Time Frame
Baseline, week 12, week 24
Title
Change in the plantar flexor muscle group spasticity
Description
Change in the plantar flexor muscle group spasticity, measured with the Modified Ashworth Scale
Time Frame
Baseline, week 12, week 24
Title
Sum of lower limb muscle spasticity
Description
Sum of the spasticity results obtained for the adductor hip, knee extensor, knee flexor and plantar flexor muscle groups
Time Frame
Baseline, week 12, week 24

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
50 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: ARSACS diagnosis must be confirmed by genetic analysis; Women and men, aged between 18 and 50 years old; Be able to perform the sit-to-stand transfer; Consent of the neurologist must be given to participate in this study; Must reside in the Saguenay-Lac-St-Jean region; Subjects must be able to give their consent freely and voluntarily. Exclusion Criteria: Patients who already meet physical activity (PA) recommendations (150 min of moderate to high intensity PA/week) or already participate in a rehabilitation program are excluded; Remain in a care facility; Do not speak English or French; Have another diagnosis causing physical limitations; Are pregnant.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Elise Duchesne, Ph.D
Phone
418-545-5011
Ext
6148
Email
elise1_duchesne@uqac.ca
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Elise Duchesne, Ph.D
Organizational Affiliation
Université du Québec à Chicoutimi
Official's Role
Principal Investigator
Facility Information:
Facility Name
Groupe de recherche interdisciplinaire sur les maladies neuromusculaires
City
Saguenay
State/Province
Quebec
ZIP/Postal Code
G7X 7X2
Country
Canada
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Elise Duchesne, Ph.D.
Phone
418-545-5011
Ext
6148
Email
elise1_duchesne@uqac.ca
First Name & Middle Initial & Last Name & Degree
Elise Duchesne, Ph.D.

12. IPD Sharing Statement

Learn more about this trial

A Home-based Rehabilitation in ARSACS

We'll reach out to this number within 24 hrs